135 related articles for article (PubMed ID: 37608771)
41. Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Hamy AS; Bonsang-Kitzis H; De Croze D; Laas E; Darrigues L; Topciu L; Menet E; Vincent-Salomon A; Lerebours F; Pierga JY; Brain E; Feron JG; Benchimol G; Lam GT; Laé M; Reyal F
Clin Cancer Res; 2019 Nov; 25(22):6731-6741. PubMed ID: 31515462
[TBL] [Abstract][Full Text] [Related]
42. Combined Assessment of the Tumor-Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer.
Ravensbergen CJ; Polack M; Roelands J; Crobach S; Putter H; Gelderblom H; Tollenaar RAEM; Mesker WE
Cells; 2021 Oct; 10(11):. PubMed ID: 34831157
[TBL] [Abstract][Full Text] [Related]
43. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.
Pan JH; Zhou H; Cooper L; Huang JL; Zhu SB; Zhao XX; Ding H; Pan YL; Rong L
Front Immunol; 2019; 10():6. PubMed ID: 30761122
[No Abstract] [Full Text] [Related]
44. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
Dieci MV; Radosevic-Robin N; Fineberg S; van den Eynden G; Ternes N; Penault-Llorca F; Pruneri G; D'Alfonso TM; Demaria S; Castaneda C; Sanchez J; Badve S; Michiels S; Bossuyt V; Rojo F; Singh B; Nielsen T; Viale G; Kim SR; Hewitt S; Wienert S; Loibl S; Rimm D; Symmans F; Denkert C; Adams S; Loi S; Salgado R;
Semin Cancer Biol; 2018 Oct; 52(Pt 2):16-25. PubMed ID: 29024776
[TBL] [Abstract][Full Text] [Related]
45. Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group.
Swisher SK; Wu Y; Castaneda CA; Lyons GR; Yang F; Tapia C; Wang X; Casavilca SA; Bassett R; Castillo M; Sahin A; Mittendorf EA
Ann Surg Oncol; 2016 Jul; 23(7):2242-8. PubMed ID: 26965699
[TBL] [Abstract][Full Text] [Related]
46. Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non-Small Cell Lung Cancer.
Lopez de Rodas M; Wang Y; Peng G; Gu J; Mino-Kenudson M; Riess JW; Velcheti V; Hellmann M; Gainor JF; Zhao H; Schalper KA
Clin Cancer Res; 2024 Mar; 30(5):998-1008. PubMed ID: 38127300
[TBL] [Abstract][Full Text] [Related]
47. Intratumoral spatial heterogeneity of tumor-infiltrating lymphocytes is a significant factor for precisely stratifying prognostic immune subgroups of microsatellite instability-high colorectal carcinomas.
Jung M; Lee JA; Yoo SY; Bae JM; Kang GH; Kim JH
Mod Pathol; 2022 Dec; 35(12):2011-2022. PubMed ID: 35869301
[TBL] [Abstract][Full Text] [Related]
48. Recent Advances in Pathology: the 2023 Annual Review Issue of The Journal of Pathology.
Jones JL; Poulsom R; Coates PJ
J Pathol; 2023 Aug; 260(5):495-497. PubMed ID: 37580852
[TBL] [Abstract][Full Text] [Related]
49. From the Immune Profile to the Immunoscore: Signatures for Improving Postsurgical Prognostic Prediction of Pancreatic Neuroendocrine Tumors.
Wei M; Xu J; Hua J; Meng Q; Liang C; Liu J; Zhang B; Wang W; Yu X; Shi S
Front Immunol; 2021; 12():654660. PubMed ID: 33968055
[TBL] [Abstract][Full Text] [Related]
50. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.
Kirilovsky A; Marliot F; El Sissy C; Haicheur N; Galon J; Pagès F
Int Immunol; 2016 Aug; 28(8):373-82. PubMed ID: 27121213
[TBL] [Abstract][Full Text] [Related]
51. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
[TBL] [Abstract][Full Text] [Related]
52. Automated quantification of stromal tumour infiltrating lymphocytes is associated with prognosis in breast cancer.
Gonzàlez-Farré M; Gibert J; Santiago-Díaz P; Santos J; García P; Massó J; Bellosillo B; Lloveras B; Albanell J; Vázquez I; Comerma L
Virchows Arch; 2023 Nov; 483(5):655-663. PubMed ID: 37500796
[TBL] [Abstract][Full Text] [Related]
53. Cyclic Multiplexed-Immunofluorescence (cmIF), a Highly Multiplexed Method for Single-Cell Analysis.
Eng J; Thibault G; Luoh SW; Gray JW; Chang YH; Chin K
Methods Mol Biol; 2020; 2055():521-562. PubMed ID: 31502168
[TBL] [Abstract][Full Text] [Related]
54. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
55. Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue.
Parra ER; Ferrufino-Schmidt MC; Tamegnon A; Zhang J; Solis L; Jiang M; Ibarguen H; Haymaker C; Lee JJ; Bernatchez C; Wistuba II
Sci Rep; 2021 Apr; 11(1):8511. PubMed ID: 33875760
[TBL] [Abstract][Full Text] [Related]
56. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images.
Saltz J; Gupta R; Hou L; Kurc T; Singh P; Nguyen V; Samaras D; Shroyer KR; Zhao T; Batiste R; Van Arnam J; ; Shmulevich I; Rao AUK; Lazar AJ; Sharma A; Thorsson V
Cell Rep; 2018 Apr; 23(1):181-193.e7. PubMed ID: 29617659
[TBL] [Abstract][Full Text] [Related]
57. Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions.
Wein L; Savas P; Luen SJ; Virassamy B; Salgado R; Loi S
Front Oncol; 2017; 7():156. PubMed ID: 28824872
[TBL] [Abstract][Full Text] [Related]
58. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
59. A template to quantify the location and density of CD3 + and CD8 + tumor-infiltrating lymphocytes in colon cancer by digital pathology on whole slides for an objective, standardized immune score assessment.
Lea D; Watson M; Skaland I; Hagland HR; Lillesand M; Gudlaugsson E; Søreide K
Cancer Immunol Immunother; 2021 Jul; 70(7):2049-2057. PubMed ID: 33439293
[TBL] [Abstract][Full Text] [Related]
60. Identification of Spatial Proteomic Signatures of Colon Tumor Metastasis: A Digital Spatial Profiling Approach.
Levy JJ; Zavras JP; Veziroglu EM; Nasir-Moin M; Kolling FW; Christensen BC; Salas LA; Barney RE; Palisoul SM; Ren B; Liu X; Kerr DA; Pointer KB; Tsongalis GJ; Vaickus LJ
Am J Pathol; 2023 Jun; 193(6):778-795. PubMed ID: 37037284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
